RabAvert, an approved inactivated virus vaccine, was included as an active comparator arm. All dose levels of RBI-4000 tested, including those as low as 0.1 mcg, elicited de novo protective immune ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and ...

RBI-4000's potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development SAN DIEGO, Feb. 7, 2025 /PRNewswire ...

Travel Health business demonstrated strong growth of 22%. Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also secured a strong foundation ...

The expected revenue is comprised of DKK 3,000 – 4,000 million from Public Preparedness vaccines, of which DKK 2,500 million have already been secured by contracts. Furthermore, approximately ...

The Rabavert market size has seen remarkable growth in recent ... to factors such as a rising focus on zoonotic disease prevention, increasing investments in vaccine research, and enhanced healthcare ...

The Rabavert market size has seen remarkable growth ... increasing investments in vaccine research, and enhanced healthcare infrastructure in emerging economies. Get Your Free Sample Market ...